Hennion & Walsh Asset Management, Inc. Rocket Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 274,259 shares of RCKT stock, worth $828,262. This represents 0.03% of its overall portfolio holdings.
Number of Shares
274,259
Previous 249,526
9.91%
Holding current value
$828,262
Previous $1.89 Million
64.55%
% of portfolio
0.03%
Previous 0.09%
Shares
13 transactions
Others Institutions Holding RCKT
# of Institutions
248Shares Held
107MCall Options Held
558KPut Options Held
177K-
Rtw Investments, LP New York, NY17.7MShares$53.4 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$38.1 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$20 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$18.7 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$15.7 Million0.68% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $229M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...